PIK3CA and breast cancer: In early‐stage breast cancer, PIK3CA mutations have been associated with slightly better 5‐year OS than PIK3CA‐wt tumors in univariable analysis, but not when correcting for clinicopathological and treatment variables (Zardavas et al, 2018).